It is well established that the PI3K/Akt/mTOR pathway plays a central
role in cell growth and proliferation. It has also been suggested that
its deregulation is associated with cancer. Genetic alterations,
involving components of this pathway, are often encountered in
endometrial cancers. Understanding and identifying the rate-limiting
steps of this pathway would be crucial for the development of novel
therapies against endometrial cancer. This paper reviews alterations in
the PI3K/Akt pathway, which could possibly contribute to the development
of endometrial cancer. In addition, potential therapeutic targets of
this pathway with emphasis on the mTOR inhibitors are also presented
